{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T20:49:12Z","timestamp":1793566152582,"version":"4.5.0"},"reference-count":76,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T00:00:00Z","timestamp":1741046400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000057","name":"NIH National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["P20GM109025"],"award-info":[{"award-number":["P20GM109025"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R35AG71476"],"award-info":[{"award-number":["R35AG71476"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R25AG083721-01"],"award-info":[{"award-number":["R25AG083721-01"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002565","name":"Alzheimer's Drug Discovery Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002565","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.neurot.2025.e00570","type":"journal-article","created":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T11:52:10Z","timestamp":1742471530000},"page":"e00570","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":85,"title":["Maximizing the benefit and managing the risk of anti-amyloid monoclonal antibody therapy for Alzheimer's disease: Strategies and research directions"],"prefix":"10.1016","volume":"22","author":[{"given":"Jeffrey L.","family":"Cummings","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.neurot.2025.e00570_bib1","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s40265-023-01858-9","article-title":"Anti-amyloid monoclonal antibodies are transformative treatments that redefine Alzheimer's disease therapeutics","volume":"83","author":"Cummings","year":"2023","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00570_bib2","article-title":"Alzheimer's disease drug development pipeline: 2024","volume":"10","author":"Cummings","year":"2024","journal-title":"Alzheimers Dement (N Y)"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00570_bib3","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/s43587-024-00611-5","article-title":"The advent of Alzheimer treatments will change the trajectory of human aging","volume":"4","author":"Selkoe","year":"2024","journal-title":"Nat Aging"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00570_bib4","doi-asserted-by":"crossref","first-page":"5481","DOI":"10.1038\/s41380-021-01249-0","article-title":"The amyloid-beta pathway in Alzheimer's disease","volume":"26","author":"Hampel","year":"2021","journal-title":"Mol Psychiatr"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00570_bib5","doi-asserted-by":"crossref","first-page":"101","DOI":"10.31887\/DCNS.2003.5.1\/hhippius","article-title":"The discovery of Alzheimer's disease","volume":"5","author":"Hippius","year":"2003","journal-title":"Dialogues Clin Neurosci"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00570_bib6","doi-asserted-by":"crossref","first-page":"595","DOI":"10.15252\/emmm.201606210","article-title":"The amyloid hypothesis of Alzheimer's disease at 25 years","volume":"8","author":"Selkoe","year":"2016","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.neurot.2025.e00570_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuint.2021.105208","article-title":"Aggregation and structure of amyloid beta-protein","volume":"151","author":"Ono","year":"2021","journal-title":"Neurochem Int"},{"issue":"22","key":"10.1016\/j.neurot.2025.e00570_bib8","doi-asserted-by":"crossref","first-page":"4757","DOI":"10.1016\/j.cell.2023.09.023","article-title":"Accelerating Alzheimer's therapeutic development: the past and future of clinical trials","volume":"186","author":"Boxer","year":"2023","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.neurot.2025.e00570_bib9","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1001\/jamaneurol.2022.3392","article-title":"Association of donanemab treatment with exploratory plasma biomarkers in early symptomatic Alzheimer disease: a secondary analysis of the TRAILBLAZER-ALZ randomized clinical trial","volume":"79","author":"Pontecorvo","year":"2022","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00570_bib10","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s13195-022-01124-2","article-title":"Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study","volume":"14","author":"McDade","year":"2022","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00570_bib11","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S1474-4422(21)00361-6","article-title":"Blood-based biomarkers for Alzheimer's disease: towards clinical implementation","volume":"21","author":"Teunissen","year":"2022","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00570_bib12","doi-asserted-by":"crossref","first-page":"8220","DOI":"10.1038\/s41467-023-43933-5","article-title":"Fatal iatrogenic cerebral beta-amyloid-related arteritis in a woman treated with lecanemab for Alzheimer's disease","volume":"14","author":"Solopova","year":"2023","journal-title":"Nat Commun"},{"issue":"8","key":"10.1016\/j.neurot.2025.e00570_bib13","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.biopsych.2020.02.001","article-title":"The beta-secretase BACE1 in Alzheimer's disease","volume":"89","author":"Hampel","year":"2021","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.neurot.2025.e00570_bib14","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.semcdb.2020.01.005","article-title":"Unraveling the complexity of gamma-secretase","volume":"105","author":"Wolfe","year":"2020","journal-title":"Semin Cell Dev Biol"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00570_bib15","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s12276-022-00754-8","article-title":"gamma-Secretase in Alzheimer's disease","volume":"54","author":"Hur","year":"2022","journal-title":"Exp Mol Med"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00570_bib16","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s40259-023-00633-2","article-title":"Anti-amyloid monoclonal antibodies for the treatment of Alzheimer's disease","volume":"38","author":"Cummings","year":"2024","journal-title":"BioDrugs"},{"key":"10.1016\/j.neurot.2025.e00570_bib17","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.neuroscience.2020.07.020","article-title":"Microglia do not take up soluble amyloid-beta peptides, but partially degrade them by secreting insulin-degrading enzyme","volume":"443","author":"Fu","year":"2020","journal-title":"Neuroscience"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00570_bib18","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1146\/annurev-immunol-101921-035222","article-title":"Immune activation in Alzheimer disease","volume":"42","author":"Mary","year":"2024","journal-title":"Annu Rev Immunol"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00570_bib19","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/s41593-023-01323-6","article-title":"The contribution of the peripheral immune system to neurodegeneration","volume":"26","author":"Berriat","year":"2023","journal-title":"Nat Neurosci"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00570_bib20","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.biopsych.2017.08.010","article-title":"Anti-amyloid-\u03b2 monoclonal antibodies for Alzheimer's disease: pitfalls and promise","volume":"83","author":"van Dyck","year":"2018","journal-title":"Biol Psychiatry"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00570_bib21","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13024-016-0115-2","article-title":"Immunotherapy targeting pyroglutamate-3 Abeta: prospects and challenges","volume":"11","author":"Cynis","year":"2016","journal-title":"Mol Neurodegener"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00570_bib22","doi-asserted-by":"crossref","first-page":"414","DOI":"10.14283\/jpad.2021.56","article-title":"Donanemab (LY3002813) phase 1b study in Alzheimer's disease: rapid and sustained reduction of brain amyloid measured by florbetapir F18 imaging","volume":"8","author":"Lowe","year":"2021","journal-title":"J\u00a0Prev Alzheimers Dis"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00570_bib23","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-61691-2","article-title":"Amyloid-beta antibody binding to cerebral amyloid angiopathy fibrils and risk for amyloid-related imaging abnormalities","volume":"14","author":"Soderberg","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.neurot.2025.e00570_bib24","doi-asserted-by":"crossref","DOI":"10.1038\/s41582-024-01053-8","article-title":"Amyloid-related imaging abnormalities: manifestations, metrics and mechanisms","author":"Greenberg","year":"2025","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00570_bib25","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2261509","article-title":"Delivery of the Brainshuttle amyloid-beta antibody fusion trontinemab to non-human primate brain and projected efficacious dose regimens in humans","volume":"15","author":"Grimm","year":"2023","journal-title":"mAbs"},{"issue":"9","key":"10.1016\/j.neurot.2025.e00570_bib26","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1056\/NEJMc2111960","article-title":"An appropriate use of accelerated approval - aducanumab for Alzheimer's disease","volume":"385","author":"Dunn","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00570_bib27","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1001\/jamainternmed.2021.4607","article-title":"Approval of aducanumab for Alzheimer disease-the FDA's perspective","volume":"181","author":"Dunn","year":"2021","journal-title":"JAMA Intern Med"},{"issue":"7618","key":"10.1016\/j.neurot.2025.e00570_bib28","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces Abeta plaques in Alzheimer's disease","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00570_bib29","doi-asserted-by":"crossref","first-page":"197","DOI":"10.14283\/jpad.2022.30","article-title":"Two randomized phase 3 studies of aducanumab in early Alzheimer's disease","volume":"9","author":"Budd","year":"2022","journal-title":"J\u00a0Prev Alzheimers Dis"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00570_bib30","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","article-title":"A\u00a0randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Abeta protofibril antibody","volume":"13","author":"Swanson","year":"2021","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00570_bib31","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer's disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.neurot.2025.e00570_bib32","doi-asserted-by":"crossref","DOI":"10.1177\/03946320231209839","article-title":"Novel anti-amyloid-beta (Abeta) monoclonal antibody lecanemab for Alzheimer's disease: a systematic review","volume":"37","author":"Chowdhury","year":"2023","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00570_bib33","doi-asserted-by":"crossref","first-page":"771","DOI":"10.14283\/jpad.2023.123","article-title":"Lecanemab Clarity AD: quality-of-life results from a randomized, double-blind phase 3 trial in early Alzheimer's disease","volume":"10","author":"Cohen","year":"2023","journal-title":"J\u00a0Prev Alzheimers Dis"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00570_bib34","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00570_bib35","doi-asserted-by":"crossref","first-page":"211","DOI":"10.14283\/jpad.2022.21","article-title":"Detection and management of amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with anti-amyloid beta therapy","volume":"9","author":"Barakos","year":"2022","journal-title":"J\u00a0Prev Alzheimers Dis"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00570_bib36","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1001\/jamaneurol.2021.4161","article-title":"Amyloid-Related Imaging Abnormalities in 2 phase 3 studies evaluating aducanumab in patients with early Alzheimer disease","volume":"79","author":"Salloway","year":"2022","journal-title":"JAMA Neurol"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00570_bib37","doi-asserted-by":"crossref","first-page":"221","DOI":"10.14283\/jpad.2022.34","article-title":"Aducanumab: appropriate use recommendations update","volume":"9","author":"Cummings","year":"2022","journal-title":"J\u00a0Prev Alzheimers Dis"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00570_bib38","doi-asserted-by":"crossref","first-page":"362","DOI":"10.14283\/jpad.2023.30","article-title":"Lecanemab: appropriate use recommendations","volume":"10","author":"Cummings","year":"2023","journal-title":"J\u00a0Prev Alzheimers Dis"},{"issue":"20","key":"10.1016\/j.neurot.2025.e00570_bib39","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1056\/NEJMoa2304430","article-title":"Two phase 3 trials of gantenerumab in early Alzheimer's disease","volume":"389","author":"Bateman","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.neurot.2025.e00570_bib40","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.1093\/brain\/awaa332","article-title":"BACE inhibition causes rapid, regional, and non-progressive volume reduction in Alzheimer's disease brain","volume":"143","author":"Sur","year":"2020","journal-title":"Brain"},{"issue":"13","key":"10.1016\/j.neurot.2025.e00570_bib41","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1212\/WNL.0b013e318230a16c","article-title":"Chronic divalproex sodium use and brain atrophy in Alzheimer disease","volume":"77","author":"Fleisher","year":"2011","journal-title":"Neurology"},{"issue":"20","key":"10.1016\/j.neurot.2025.e00570_bib42","doi-asserted-by":"crossref","first-page":"e2114","DOI":"10.1212\/WNL.0000000000207156","article-title":"Accelerated brain volume loss caused by anti-beta-amyloid drugs: a systematic review and meta-analysis","volume":"100","author":"Alves","year":"2023","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00570_bib43","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1111\/j.1530-0277.1995.tb01598.x","article-title":"Longitudinal changes in magnetic resonance imaging brain volumes in abstinent and relapsed alcoholics","volume":"19","author":"Pfefferbaum","year":"1995","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.neurot.2025.e00570_bib44","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.nicl.2017.09.002","article-title":"Short-term mechanisms influencing volumetric brain dynamics","volume":"16","author":"Dieleman","year":"2017","journal-title":"Neuroimage Clin"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00570_bib45","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S1474-4422(24)00335-1","article-title":"Brain volume change following anti-amyloid beta immunotherapy for Alzheimer's disease: amyloid-removal-related pseudo-atrophy","volume":"23","author":"Belder","year":"2024","journal-title":"Lancet Neurol"},{"issue":"18","key":"10.1016\/j.neurot.2025.e00570_bib46","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in early Alzheimer's disease","volume":"384","author":"Mintun","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.neurot.2025.e00570_bib48","doi-asserted-by":"crossref","first-page":"9037","DOI":"10.1002\/alz.14336","article-title":"Centiloid recommendations for clinical context-of-use from the AMYPAD consortium","volume":"20","author":"Collij","year":"2024","journal-title":"Alzheimers Dement"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00570_bib49","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1001\/jamaneurol.2022.2793","article-title":"Association of amyloid reduction after donanemab treatment with tau pathology and clinical outcomes: the TRAILBLAZER-ALZ randomized clinical trial","volume":"79","author":"Shcherbinin","year":"2022","journal-title":"JAMA Neurol"},{"issue":"9","key":"10.1016\/j.neurot.2025.e00570_bib50","doi-asserted-by":"crossref","first-page":"e1347","DOI":"10.1212\/WNL.0000000000011524","article-title":"Alzheimer's Disease Neuroimaging I. Temporal dynamics of beta-amyloid accumulation in aging and Alzheimer disease","volume":"96","author":"Jagust","year":"2021","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00570_bib51","doi-asserted-by":"crossref","first-page":"e619","DOI":"10.1212\/WNL.0000000000011214","article-title":"Defining the lowest threshold for amyloid-PET to predict future cognitive decline and amyloid accumulation","volume":"96","author":"Farrell","year":"2021","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.neurot.2025.e00570_bib53","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1007\/s00259-021-05191-9","article-title":"Relationship between amyloid and tau levels and its impact on tau spreading","volume":"48","author":"Dore","year":"2021","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"12","key":"10.1016\/j.neurot.2025.e00570_bib54","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1212\/WNL.44.12.2315","article-title":"The Clinician Interview-Based Impression (CIBI): a clinician's global change rating scale in Alzheimer's disease","volume":"44","author":"Knopman","year":"1994","journal-title":"Neurology"},{"issue":"13","key":"10.1016\/j.neurot.2025.e00570_bib55","doi-asserted-by":"crossref","first-page":"853","DOI":"10.2165\/00023210-200418130-00003","article-title":"Activities of daily living in patients with dementia: clinical relevance, methods of assessment and effects of treatment","volume":"18","author":"Desai","year":"2004","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neurot.2025.e00570_bib56","series-title":"Guidance for industry. U.S. Department of health and human services; Food and drug administration; center for drug evaluation and research (CDER)","article-title":"Early Alzheimer's disease: developing drugs for treatment","year":"2024"},{"key":"10.1016\/j.neurot.2025.e00570_bib57","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.trci.2019.06.005","article-title":"Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer's disease clinical trials","volume":"5","author":"Andrews","year":"2019","journal-title":"Alzheimers Dement (N Y)."},{"issue":"3","key":"10.1016\/j.neurot.2025.e00570_bib58","article-title":"Meaningful benefit and minimal clinically important difference (MCID) in Alzheimer's disease: open peer commentary","volume":"9","author":"Cummings","year":"2023","journal-title":"Alzheimers Dement (N Y)"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00570_bib59","doi-asserted-by":"crossref","first-page":"595","DOI":"10.14283\/jpad.2023.50","article-title":"'Time Saved' as a demonstration of clinical meaningfulness and illustrated using the donanemab TRAILBLAZER-ALZ Study findings","volume":"10","author":"Dickson","year":"2023","journal-title":"J\u00a0Prev Alzheimers Dis"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00570_bib60","article-title":"Assessing the clinical meaningfulness of slowing CDR-SB progression with disease-modifying therapies for Alzheimers disease","volume":"11","author":"Hartz","year":"2025","journal-title":"Alzheimers Dement (N Y)"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00570_bib61","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1002\/alz.12959","article-title":"Expectations and clinical meaningfulness of randomized controlled trials","volume":"19","author":"Petersen","year":"2023","journal-title":"Alzheimers Dement"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00570_bib62","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s40120-022-00350-y","article-title":"Long-term health outcomes of lecanemab in patients with early Alzheimer's disease using simulation modeling","volume":"11","author":"Tahami Monfared","year":"2022","journal-title":"Neurol Ther"},{"issue":"19","key":"10.1016\/j.neurot.2025.e00570_bib63","doi-asserted-by":"crossref","first-page":"e1837","DOI":"10.1212\/WNL.0000000000207770","article-title":"Eligibility for anti-amyloid treatment in a population-based study of cognitive aging","volume":"101","author":"Pittock","year":"2023","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00570_bib64","first-page":"2716","article-title":"Real-word application of the AT(N) classification and disease-modifying treatment eligibility in a hospital-based cohort","volume":"271","author":"Canu","year":"2024","journal-title":"J\u00a0Neurol"},{"issue":"19","key":"10.1016\/j.neurot.2025.e00570_bib65","doi-asserted-by":"crossref","first-page":"e2102","DOI":"10.1212\/WNL.0000000000201043","article-title":"beta-amyloid, tau, neurodegeneration classification and eligibility for anti-amyloid treatment in a memory clinic population","volume":"99","author":"Rosenberg","year":"2022","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00570_bib66","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s13195-024-01521-9","article-title":"Clinical application of plasma P-tau217 to assess eligibility for amyloid-lowering immunotherapy in memory clinic patients with early Alzheimer's disease","volume":"16","author":"Howe","year":"2024","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.neurot.2025.e00570_bib68","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13195-016-0201-2","article-title":"Older patients are still under-represented in clinical trials of Alzheimer's disease","volume":"8","author":"Banzi","year":"2016","journal-title":"Alzheimers Res Ther"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00570_bib69","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0124500","article-title":"Systematic review: representativeness of participants in RCTs of acetylcholinesterase inhibitors","volume":"10","author":"Leinonen","year":"2015","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00570_bib70","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/alz.12433","article-title":"Diversity in Alzheimer's disease drug trials: the importance of eligibility criteria","volume":"18","author":"Franzen","year":"2022","journal-title":"Alzheimers Dement"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00570_bib71","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/ana.26819","article-title":"Eligibility rates among racially and ethnically diverse US participants in phase 2 and phase 3 placebo-controlled, double-blind, randomized trials of lecanemab and elenbecestat in early Alzheimer disease","volume":"95","author":"Grill","year":"2024","journal-title":"Ann Neurol"},{"issue":"8","key":"10.1016\/j.neurot.2025.e00570_bib72","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/S1474-4422(22)00168-5","article-title":"Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials","volume":"21","author":"Ossenkoppele","year":"2022","journal-title":"Lancet Neurol"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00570_bib73","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/s43587-023-00403-3","article-title":"Blood biomarkers for Alzheimer's disease in clinical practice and trials","volume":"3","author":"Hansson","year":"2023","journal-title":"Nat Aging"},{"issue":"8","key":"10.1016\/j.neurot.2025.e00570_bib74","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s40263-024-01103-1","article-title":"Alzheimer's disease: combination therapies and clinical trials for combination therapy development","volume":"38","author":"Cummings","year":"2024","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neurot.2025.e00570_bib75","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2023.1279740","article-title":"Gamma-secretase modulators: a promising route for the treatment of Alzheimer's disease","volume":"16","author":"Nordvall","year":"2023","journal-title":"Front Mol Neurosci"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00570_bib76","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s13311-013-0187-4","article-title":"Developing therapeutic antibodies for neurodegenerative disease","volume":"10","author":"Yu","year":"2013","journal-title":"Neurotherapeutics"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00570_bib77","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1056\/NEJMoa2308719","article-title":"Ultrasound blood-brain barrier opening and aducanumab in Alzheimer's disease","volume":"390","author":"Rezai","year":"2024","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00570_bib78","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S1474-4422(23)00508-2","article-title":"A\u00a0chance to prevent Alzheimer's disease sooner than you think","volume":"23","author":"Reiman","year":"2024","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00570_bib79","doi-asserted-by":"crossref","DOI":"10.1002\/alz.14342","article-title":"The case for regulatory approval of amyloid-lowering immunotherapies in Alzheimer's disease based on clearcut biomarker evidence","volume":"21","author":"Aisen","year":"2025","journal-title":"Alzheimers Dement"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747925000480?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747925000480?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T08:01:30Z","timestamp":1777622490000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747925000480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":76,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S1878747925000480"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2025.e00570","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Maximizing the benefit and managing the risk of anti-amyloid monoclonal antibody therapy for Alzheimer's disease: Strategies and research directions","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2025.e00570","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author. Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e00570"}}